{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-010427","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.305646+00:00","generated_at":"2026-06-04T04:25:48.254728+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen enrolls first patient in PALISADE-3 Phase 3 fasedienol trial for social anxiety disorder","bullets":["PALISADE-3 is a randomized, double-blind, placebo-controlled study of ~236 adults aged 18–65 with SAD.","Primary endpoint is patient-rated SUDS; patients randomized 1:1 to fasedienol or placebo.","Follows positive PALISADE-2 results; PALISADE-4 replication planned for H2 2024.","Social anxiety disorder affects over 25 million Americans; fasedienol is an investigational pherine.","CEO Shawn Singh calls the initiation a 'major milestone' toward first-in-class treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-010427","json":"https://secwatch.observer/filing/0001437749-24-010427.json","markdown":"https://secwatch.observer/filing/0001437749-24-010427.md","text":"https://secwatch.observer/filing/0001437749-24-010427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924010427/0001437749-24-010427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924010427/vtgn20240401_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:25:48.254728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}